Robert DeLuca - Orexo AB President of Orexo US Inc.

ORX Stock  SEK 18.20  0.70  4.00%   

President

Mr. Robert A. DeLuca was President of Orexo US Inc. within Orexo AB since 2013. He has experience from establishing commercial operations in the United States, as well as experience within managed care, marketing and sales from various managing positions at SanofiAventis, ScheringPlough, Berlex, Pharmacia and most recently as Chief Commercial Officer of Archimedes Pharmaceuticals. He is Member of the St. Johns College of Pharmacy Deans Advisory Board, American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations. since 2013.
Age 62
Tenure 11 years
Phone46 1 87 80 88 00
Webhttps://www.orexo.com

Orexo AB Management Efficiency

The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.
Orexo AB has accumulated 519 M in total debt with debt to equity ratio (D/E) of 69.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orexo AB has a current ratio of 2.17, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orexo AB until it has trouble settling it off, either with new capital or with free cash flow. So, Orexo AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orexo AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orexo to invest in growth at high rates of return. When we think about Orexo AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

PRESIDENT Age

Urban PaulssonCamurus AB
56
Kristoffer HanssonBioInvent International AB
49
Torsten MalmstromCamurus AB
55
Fredrik JoabssonCamurus AB
51
Agneta SvedbergCamurus AB
56
Orexo AB , a specialty pharmaceutical company, develops products based on proprietary drug delivery technology. Orexo AB was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 130 people. Orexo AB (ORX) is traded on Stockholm Exchange in Sweden and employs 126 people.

Management Performance

Orexo AB Leadership Team

Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fredrik Jarrsten, Ex CFO
MD MBA, Chief Officer
Cecilia Coupland, Vice President and Head of Operations
Nikolaj Sorensen, Pres CEO
Lena Wange, Investor Relations & Communications Manager
Jesper Lind, Advisor
Dennis Urbaniak, Ex Therapeutics
Robert DeLuca, President of Orexo US Inc.
Robert Ronn, Vice President and Head of Research & Development

Orexo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Orexo Stock Analysis

When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.